Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Muyu Kuang
Observed name:
Kuang, Muyu
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Huadong Hospital,
State Key Laboratory of Genetic Engineering
ORCID:
0000-0001-7052-6524
Observed ORCID:
0000-0001-7052-6524
OpenAlex ID:
A5083862505
Genomic and immune profiling of pre-invasive lung adenocarcinoma
2019
·
Haiquan Chen
, Jian Carrot-Zhang
, et al.
·
Nature Communications
·
281
PDF
Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma
2018
·
Muyu Kuang
, Xuxia Shen
, et al.
·
American Journal of Clinical Pathology
·
44
PDF
FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules
2019
·
Muyu Kuang
, Yizhou Peng
, et al.
·
Clinical and Experimental Medicine
·
41
The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma
2020
·
Zhenhua Zhou
, Yan Li
, et al.
·
EBioMedicine
·
39
A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks
2021
·
Chongze Yuan
, Haojie Chen
, et al.
·
Genome biology
·
35
PDF
Super enhancer associated RAI14 is a new potential biomarker in lung adenocarcinoma
2017
·
Chongze Yuan
, Hong Hu
, et al.
·
Oncotarget
·
33
PDF
tRNA‐based prognostic score in predicting survival outcomes of lung adenocarcinomas
2019
·
Muyu Kuang
, Difan Zheng
, et al.
·
International Journal of Cancer
·
23
PDF
Proteomic analysis of plasma exosomes to differentiate malignant from benign pulmonary nodules
2019
·
Muyu Kuang
, Xiaoting Tao
, et al.
·
Clinical Proteomics
·
23
PDF
EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis
2020
·
Yue Zhao
, Yunjian Pan
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
22
ALCAM+ stromal cells: role in giant cell tumor of bone progression
2018
·
Zhenhua Zhou
, Yan Li
, et al.
·
Cell Death and Disease
·
20
PDF
First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC
2026
·
Dongmei Ji
, Wenmin Fu
, et al.
·
BMC Medicine
·
14
A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.
2022
·
Dongmei Ji
, Weina Shen
, et al.
·
Journal of Clinical Oncology
·
8
Prognostic prediction of lung adenocarcinoma by integrative analysis of RHOH expression and methylation
2023
·
Muyu Kuang
, Zhenhua Zhou
, et al.
·
The Clinical Respiratory Journal
·
3
PDF
A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
2023
·
Dongmei Ji
, Lijie Song
, et al.
·
Journal of Clinical Oncology
·
1
Corrigendum to “The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma” [EBioMedicine 51(2020)102598]
2021
·
Zhenhua Zhou
, Yan Li
, et al.
·
EBioMedicine
·
1
Magnetically targeted high-entropy oxide nanozymes induce ROS-associated immunogenic cell death for catalytic-immunotherapy
2026
·
Peng Yan
, Zihang Zhao
, et al.
·
Chemical Engineering Journal
Show more works
View as search
Works count:
31
Citation count:
588
H-index:
11
I10-index:
11
Year
Topic
Type